Astellas Oncology Announces New Data in Acute Myeloid Leukemia to be Presented at the 2016 ASH Annual Meeting
- Complete results of Phase 1/2 CHRYSALIS trial of gilteritinib in patients with Relapsed/Refractory AML to be presented during Oral Session on Dec. 5 -
NORTHBROOK, Ill., Nov. 17, 2016 /PRNewswire/ -- Astellas today announced two gilteritinib abstracts, including an oral presentation in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML), that will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, Dec. 3-6 in San Diego.
The following abstract will be presented during an oral presentation session:
Title: Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). (Abstract 1069)
Presenter: Alexander E. Perl, M.D., University of Pennsylvania-Abramson Comprehensive Cancer Center, Philadelphia, Pa.
- Session Date/Time: Monday, Dec. 5 at 4:30 p.m. PST
- Location: San Diego Ballroom AB (Marriott Marquis San Diego Marina)
In addition to the oral presentation, Astellas will present the following abstract in a poster session:
Title: Gilteritinib (ASP2215), a Novel FLT3/AXL Inhibitor: Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia (Yoko Ueno, PhD) (Abstract 2830)
- Session Date/Time: Sunday, Dec. 4 from 6:00 p.m. to 8:00 p.m. PST
- Location: Hall GH (San Diego Convention Center)
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.
Logo - http://photos.prnewswire.com/prnh/20140416/84970
For further information: For Media, Tyler Marciniak, (847) 736-7145, firstname.lastname@example.org; For Investors, So Sekine, (847) 224-9557, email@example.com